SMO ClinPlusLTD Past Earnings Performance
Past criteria checks 1/6
SMO ClinPlusLTD has been growing earnings at an average annual rate of 28.3%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 21.2% per year. SMO ClinPlusLTD's return on equity is 9.3%, and it has net margins of 13.1%.
Key information
28.3%
Earnings growth rate
21.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 21.2% |
| Return on equity | 9.3% |
| Net Margin | 13.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How SMO ClinPlusLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 810 | 106 | 65 | 35 |
| 30 Jun 24 | 806 | 128 | 65 | 35 |
| 31 Mar 24 | 787 | 132 | 63 | 37 |
| 31 Dec 23 | 760 | 135 | 61 | 35 |
| 30 Sep 23 | 729 | 135 | 54 | 34 |
| 30 Jun 23 | 690 | 115 | 54 | 34 |
| 31 Mar 23 | 621 | 88 | 52 | 32 |
| 01 Jan 23 | 586 | 72 | 56 | 32 |
| 30 Sep 22 | 542 | 52 | 52 | 29 |
| 30 Jun 22 | 523 | 50 | 49 | 26 |
| 31 Mar 22 | 528 | 58 | 53 | 29 |
| 31 Dec 21 | 503 | 58 | 40 | 21 |
| 30 Sep 21 | 472 | 58 | 67 | 30 |
| 30 Jun 21 | 421 | 53 | 38 | 17 |
| 31 Mar 21 | 373 | 46 | 44 | 15 |
| 31 Dec 20 | 335 | 35 | 44 | 15 |
| 31 Dec 19 | 304 | 52 | 24 | 16 |
| 31 Dec 18 | 193 | 30 | 17 | 12 |
| 30 Sep 18 | 172 | 29 | 12 | 11 |
| 30 Jun 18 | 147 | 26 | 16 | 5 |
| 31 Mar 18 | 132 | 23 | 16 | 3 |
| 31 Dec 17 | 116 | 20 | 11 | 5 |
| 30 Sep 17 | 98 | 14 | 10 | 3 |
| 30 Jun 17 | 80 | 9 | 10 | 1 |
| 31 Mar 17 | 72 | 8 | 9 | 0 |
| 31 Dec 16 | 63 | 8 | 8 | 0 |
| 31 Dec 15 | 42 | -14 | 24 | 0 |
Quality Earnings: 301257 has a high level of non-cash earnings.
Growing Profit Margin: 301257's current net profit margins (13.1%) are lower than last year (18.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301257's earnings have grown significantly by 28.3% per year over the past 5 years.
Accelerating Growth: 301257's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301257 had negative earnings growth (-21.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).
Return on Equity
High ROE: 301257's Return on Equity (9.3%) is considered low.